 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | JSC Pharmasyntez |
| Street 1: | Presnenskay emb., 12 |
| Street 2: | |
| City: | Moscow |
| Province: | |
| Post Code: | 123100 |
| Country: | Russian Federation |
| Phone: | +7 495 750 5437 |
| Organization Email: | moscow@pharmasyntez.com |
| Web Site: | http://www.pharmasyntez.com |
| Other Online Presence: | |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | Private sector |
| Is your organization legally registered in your country: | Yes |
| If yes, please enter your registration number: | |
| Organization Type - Primary: | Private Sector |
| Organization Type - Secondary: | Company |
| Organization Description: | |
| JSC “Pharmasyntez” mission is to produce the latest pharmaceutical products of the highest quality that is available to patients, healthcare administrations and our partners. We are committed in the development and productions of innovative drugs. We are the only Russian Pharmaceutical company to develop a New Chemical Entity (NCE) “PERHLOZONE” for the treatment of Multi-Drug Resistant Tuberculosis (MDRTB). Our primary focus is to develop and manufacture innovative pharmaceuticals for the treatment of diseases which are socially significant like Anti-TB, Oncology, ARV’s and immune-modulators. Overall the primary mission of the company is to “Develop and manufacture innovative quality pharmaceuticals with a social responsibility” | |
| Do you know about the UNHLM declaration: | |
Specializations / Areas of Work | |
|
Provision of drugs, diagnostics and commodities Research and Development |
Other Organization Information | |
| Total number of staff in your organization: | 100 + |
| Number of full-time staff who are directly involved with TB: | 100 + |
| Number of part-time staff who are directly involved with TB: | 100 + |
| Number of volunteers who are directly involved with TB: | 1 - 5 |
| How did you hear about the Stop TB Partnership: | Internet search |
| If you were informed or referred by another partner of the Stop TB Partnership please tell us who: | |
| Why do you wish join the Stop TB Partnership: | Network with other partners |
| Are you a member of a Stop TB national partnership: | No |
| Are you in contact with your national TB programme: | No |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| AntiTB drugs production and distribution | |
Geographical Reach | |
| Which country is your headquarters located in: | Russian Federation |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
Eswatini India Indonesia Iran (Islamic Republic of) Iraq Ireland Israel Italy Jamaica Japan Jordan Kazakhstan Kenya Kiribati Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Lithuania Luxembourg Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Micronesia (Federated States of) Monaco Mongolia Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Zealand Nicaragua Niger Nigeria Niue Norway Oman Pakistan Palau Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Qatar Republic of Korea Republic of Moldova Republic of Montenegro Republic of Serbia Romania Russian Federation Rwanda Saint Kitts and Nevis Saint Lucia Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Sudan Spain Sri Lanka Sudan Suriname Sweden Switzerland Syrian Arab Republic Tajikistan Thailand The Former Yugoslav Rep of Macedonia Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Tuvalu Uganda Ukraine United Arab Emirates United Kingdom of Great Britain and Northern Ireland United Republic of Tanzania United States of America Uruguay |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
Drug-Resistant TB: Has conducted 3 Phase clinical trials on novel anti MDR TB drug Perchlozone. TB-HIV: Will continue clinical studies on novel antiTB drugs in HIV positive patients (safety and including drug to drug interactions) Laboratory Strengthening: Has own laboratory New TB Drugs: Has Phase 3 finished novel antiTB and anti MDR TB drug Perchlozone Have several new substances to be studied Fundamental Research: Searching for new antiTB drugs and moleculs Research: New treatment regimen development |
|
Declaration | |
| Declaration of interests: No conflicts of interest were delacred. | |
| Application date: | July 9, 2012 |
| Last updated: | January 24, 2017 |